entertainment -WSS

entertainment

author：explore 2025-09-30 14:34:43 - browse：2541

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Anavex keeps shifting the goalposts in its clinical trials

hotspot

WSS

What will Novo Nordisk's VC do with its influx of cash?

South Korea throws huge K

Some top drug companies are starting to take action on climate

European officials brace for rough respiratory virus season

European officials brace for rough respiratory virus season

NIH trials fail to test meaningful long Covid therapies, experts say

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

IVG is promising — but it won’t replace IVF quite yet

Medicare details structure of new drug price negotiation program

Drastic changes should bring profitability, startup health insurers say

Trump demands the U.S. pay no more for drugs than other countries … again

Setback for rare diseases as Taysha Gene Therapies pulls back

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Wegovy trial has doctors encouraged over new possibilities

As demand for Covid shots wanes, Moderna seeks its next success

Some top drug companies are starting to take action on climate

knowledge

Stop Congress from blocking public access to science

Naloxone nonprofit donates 200,000 doses after FDA approval

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

The Karikó problem: Lessons for funding basic research

Nobel honors Karikó and Weissman's enduring partnership

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

hotspot

focus

hotspot

focus